AAAAAA

   
Results: 1-11 |
Results: 11
Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes
Authors: Temple, R Allen, E Fordham, J Phipps, S Schneider, HC Lindauer, K Hayes, I Lockey, J Pollock, K Jupp, R
Citation: R. Temple et al., Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes, AM J RESP C, 25(4), 2001, pp. 425-433
Placebo-controlled trials - Response
Authors: Temple, R Ellenberg, SS
Citation: R. Temple et Ss. Ellenberg, Placebo-controlled trials - Response, ANN INT MED, 135(1), 2001, pp. 63-64
The Food and Drug Administration
Authors: Glaser, V Temple, R
Citation: V. Glaser et R. Temple, The Food and Drug Administration, J ANTI-AG M, 3(3), 2000, pp. 229-234
Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues
Authors: Temple, R Ellenberg, SS
Citation: R. Temple et Ss. Ellenberg, Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues, ANN INT MED, 133(6), 2000, pp. 455-463
Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases
Authors: Ellenberg, SS Temple, R
Citation: Ss. Ellenberg et R. Temple, Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases, ANN INT MED, 133(6), 2000, pp. 464-470
Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials
Authors: Temple, R
Citation: R. Temple, Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials, AM HEART J, 139(4), 2000, pp. S133-S135
Patients, physicians, and clinical trials: The other side of the coins
Authors: Flexner, C Abramson, SB Snyderman, R Dieterich, DT Korn, D Temple, R Sherwood, L Goldblatt, D
Citation: C. Flexner et al., Patients, physicians, and clinical trials: The other side of the coins, J INVES MED, 47(8), 1999, pp. 343-357
Are surrogate markers adequate to assess cardiovascular disease drugs?
Authors: Temple, R
Citation: R. Temple, Are surrogate markers adequate to assess cardiovascular disease drugs?, J AM MED A, 282(8), 1999, pp. 790-795
Higher standards for epidemiologic studies-replication prior to publication? Reply
Authors: Temple, R
Citation: R. Temple, Higher standards for epidemiologic studies-replication prior to publication? Reply, J AM MED A, 282(10), 1999, pp. 937-938
Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance
Authors: Temple, R
Citation: R. Temple, Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance, J AM MED A, 281(9), 1999, pp. 841-844
Role of government agencies regarding cost-effectiveness claims: FDA perspective
Authors: Temple, R
Citation: R. Temple, Role of government agencies regarding cost-effectiveness claims: FDA perspective, AM HEART J, 137(5), 1999, pp. S75-S77
Risultati: 1-11 |